What is the difference between Cetrorelix and hCG?

Cetrorelix: Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression hCG: Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via LH-receptor-driven intratesticular testosterone

Is Cetrorelix FDA approved?

Cetrorelix is FDA approved. This regulatory status is provided for research and educational context only.

hCG is FDA approved (FDA status current as of 2000-09-20). This regulatory status is provided for research and educational context only.

How is Cetrorelix administered in research settings?

In research settings, Cetrorelix is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is hCG administered in research settings?

In research settings, hCG is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cetrorelix vs hCG

Peptide Comparison

Cetrorelix vs hCG

Both are Reproductive & Hormonal peptides.

Cetrorelix

Cetrotide

Sexual HealthFDA ApprovedPrescription

Half-life: ~62 hours

1 providers listed

Full Cetrorelix profile →

hCG

Human Chorionic Gonadotropin

Sexual HealthFDA ApprovedPrescription

Half-life: ~24-36 hours

41 providers listed

Full hCG profile →

Bottom line

Cetrorelix has a longer half-life than hCG, so it generally needs less frequent dosing.

Quick Verdict

Cetrorelix

Half-life

~62 hours

hCG

Half-life

~24-36 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	hCG
Less frequent dosing (longer half-life)	Cetrorelix
More provider options (1 vs 41)	hCG

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cetrorelix

hCG

Mechanism Family

Reproductive & Hormonal

Half-life

~62 hours

~24-36 hours

FDA Status

approved

Admin Routes

subcutaneous

subcutaneous, intramuscular

Availability

Prescription

Providers

1 listed

41 listed

FDA Update

—

Sep 2000

Avail. Notes

FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.

FDA-approved prescription drug (Pregnyl, Novarel, NDA 019478). Approved for fertility and male hypogonadism. FDA banned OTC homeopathic hCG Dec 2011. Prescription Rx products remain approved.

Research Evidence

Cetrorelix

Meta-analysis · 7 key studies · most recent 2026

hCG

Meta-analysis · 73 key studies · most recent 2026

Research Citations

Cetrorelix

Meta-analysis2026 · J Coll Physicians Surg Pak

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.

Meta-analysis2023 · Hum Reprod Update

Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analy…

Cohort2026 · Int J Reprod Biomed

Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation…

Cohort2021 · BMC Pregnancy and Childbirth

Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study

+3 more

hCG

Meta-analysis2026 · Gynecol Obstet Invest

Efficacy of Double Trigger versus hCG Trigger Alone in GnRH-Antagonist Cycles: A Systematic Review and Meta-A…

RCT2026 · J Ovarian Res

Comparative efficacy of human chorionic gonadotropin alone versus dual trigger for oocyte maturation in advan…

Meta-analysis2026 · Hum Reprod Update

Intrauterine human chorionic gonadotropin administration before embryo transfer (IHABT): an individual partic…

RCT2024 · JBRA Assist Reprod

Sublingual human chorionic gonadotropin as an adjuvant to ovulation induction.

+69 more

About Cetrorelix

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Research Areas

HPG axis suppressionLH/FSH reductioncontrolled ovarian stimulation supporttestosterone management

About hCG

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via LH-receptor-driven intratesticular testosterone

Research Areas

direct Leydig cell LH-receptor stimulation for testosterone productiontesticular volume maintenance during testosterone therapyIVF oocyte maturation trigger in female fertility protocolsdose-dependent estradiol increase — aromatization monitoring relevant

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cetrorelix

Absolute Contraindications

Pregnancy — contraindicatedLactation — contraindicated

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

hCG

Reported (Unverified — Pending Clinical Review)

hormone-sensitive cancerspolycythemiaprecocious puberty

No established clinical contraindications

Suggested Monitoring

Total testosteroneLHFSHEstradiol (E2)SHBGProlactin

Standard reproductive endocrinology panels establish HPG axis baseline before hCG use. Testosterone and E2 confirm gonadal response; LH suppression during treatment is an expected finding.

Find Providers

Where to source these peptides

Providers offering

Cetrorelix

1 listed

Browse directory →

Providers offering

hCG

41 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Reproductive & Hormonal Comparisons

Browse all peptides →

Educational research tools — not medical advice.